MX2015009690A - Anticuerpos anti-flt-1 para tratar la distrofia muscular de duchenne. - Google Patents

Anticuerpos anti-flt-1 para tratar la distrofia muscular de duchenne.

Info

Publication number
MX2015009690A
MX2015009690A MX2015009690A MX2015009690A MX2015009690A MX 2015009690 A MX2015009690 A MX 2015009690A MX 2015009690 A MX2015009690 A MX 2015009690A MX 2015009690 A MX2015009690 A MX 2015009690A MX 2015009690 A MX2015009690 A MX 2015009690A
Authority
MX
Mexico
Prior art keywords
muscular dystrophy
flt
duchenne muscular
antibodies
dmd
Prior art date
Application number
MX2015009690A
Other languages
English (en)
Other versions
MX360153B (es
Inventor
Lawrence Charnas
Serene Josiah
Thomas M Luby
Dennis Keefe
Atsushi Asakura
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of MX2015009690A publication Critical patent/MX2015009690A/es
Publication of MX360153B publication Critical patent/MX360153B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención proporciona, entre otras cosas, métodos y composiciones para tratar la distrofia muscular, en particular, la distrofia muscular de Duchenne (DMD); en algunas modalidades, un método de acuerdo con la presente invención incluye la administración a un individuo que padece o es susceptible a DMD de una cantidad eficaz de un anticuerpo anti-Flt-1, o fragmento de unión al antígeno de este, de manera que se reduzca la intensidad, gravedad o frecuencia de al menos un síntoma o característica de la DMD, o se retrase el inicio de esta.
MX2015009690A 2013-01-28 2014-01-28 Anticuerpos anti-flt-1 para tratar la distrofia muscular de duchenne. MX360153B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361757571P 2013-01-28 2013-01-28
PCT/US2014/013402 WO2014117160A1 (en) 2013-01-28 2014-01-28 Anti-flt-1 antibodies in treating duchenne muscular dystrophy

Publications (2)

Publication Number Publication Date
MX2015009690A true MX2015009690A (es) 2016-03-31
MX360153B MX360153B (es) 2018-10-24

Family

ID=50073518

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015009690A MX360153B (es) 2013-01-28 2014-01-28 Anticuerpos anti-flt-1 para tratar la distrofia muscular de duchenne.

Country Status (14)

Country Link
US (3) US9957324B2 (es)
EP (1) EP2948476B1 (es)
JP (2) JP6469022B2 (es)
KR (1) KR102259255B1 (es)
CN (1) CN104955843B (es)
AU (1) AU2014209012B2 (es)
BR (1) BR112015017242B1 (es)
CA (1) CA2898998C (es)
EA (1) EA037501B1 (es)
ES (1) ES2676406T3 (es)
HK (2) HK1213918A1 (es)
IL (1) IL238588B (es)
MX (1) MX360153B (es)
WO (1) WO2014117160A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014117155A1 (en) 2013-01-28 2014-07-31 Shire Human Genetic Therapies, Inc. Placenta growth factor in treating duchenne muscular dystrophy
BR112017021416A2 (pt) 2015-04-07 2018-07-03 Shire Human Genetic Therapies anticorpos anti-flt-1 no tratamento de displasia broncopulmonar.
MA41908A (fr) * 2015-04-07 2021-03-31 Shire Human Genetic Therapies Anticorps anti-flt-1 utilisés dans le traitement de la dysplasie bronchopulmonaire
MA41899A (fr) * 2015-04-07 2018-02-13 Shire Human Genetic Therapies Anticorps anti-flt-1 pour traiter la dystrophie musculaire de duchenne
KR102019048B1 (ko) 2017-02-06 2019-09-09 가톨릭대학교 산학협력단 MG53과 Orai1의 결합을 이용한 근육긴장저하 치료제 스크리닝 방법
KR101886788B1 (ko) 2017-02-07 2018-08-09 가톨릭대학교 산학협력단 MG53과 Orai1의 결합을 이용한 뒤시엔느 골격근 위축증 치료제 스크리닝 방법
KR20230140362A (ko) 2022-03-24 2023-10-06 주식회사 케이에스비튜젠 항-Fetuin-B 항체 및 해당 항체를 유효 성분으로 포함하는 근육질환의 예방, 치료 또는 개선용 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1819358T1 (sl) * 2004-11-18 2014-10-30 Imclone Llc Protitelesa proti receptorju 1 za vaskularni endotelijski rastni dejavnik (vegfr-1)

Also Published As

Publication number Publication date
JP2019023230A (ja) 2019-02-14
EP2948476B1 (en) 2018-06-06
AU2014209012B2 (en) 2018-11-08
CN104955843B (zh) 2019-08-13
US20210163603A1 (en) 2021-06-03
AU2014209012A1 (en) 2015-05-21
EP2948476A1 (en) 2015-12-02
KR102259255B1 (ko) 2021-05-31
US9957324B2 (en) 2018-05-01
US20150361174A1 (en) 2015-12-17
ES2676406T3 (es) 2018-07-19
WO2014117160A1 (en) 2014-07-31
IL238588A0 (en) 2015-06-30
JP2016511234A (ja) 2016-04-14
US20180312593A1 (en) 2018-11-01
BR112015017242A2 (es) 2017-08-15
CA2898998C (en) 2023-02-14
MX360153B (es) 2018-10-24
KR20150109386A (ko) 2015-10-01
IL238588B (en) 2020-04-30
BR112015017242B1 (pt) 2023-11-07
JP6469022B2 (ja) 2019-02-13
CA2898998A1 (en) 2014-07-31
EA201590720A8 (ru) 2018-09-28
EA037501B1 (ru) 2021-04-05
CN104955843A (zh) 2015-09-30
EA201590720A1 (ru) 2015-11-30
HK1213918A1 (zh) 2016-07-15
HK1217710A1 (zh) 2017-01-20

Similar Documents

Publication Publication Date Title
MX2015009690A (es) Anticuerpos anti-flt-1 para tratar la distrofia muscular de duchenne.
MX362105B (es) Folistatina en el tratamiento de distrofia muscular de duchenne.
PH12020550214A1 (en) Antibodies specific to cd47 and pd-l1
MX2022002364A (es) Anticuerpos anti-pd-l1.
PH12017500229A1 (en) Combination therapies with anti cd40 antibodies
MX2021015309A (es) Composiciones para el tratamiento de la artritis reumatoide y metodos para su uso.
NZ728688A (en) Anti-pd-1 antibodies
WO2019014328A3 (en) AGONISTIC ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF
MX2018007630A (es) Anticuerpos contra la metaloproteinasa de matriz 9.
PH12015501505A1 (en) Antibodies that bind to tl1a and their uses
MX2017001959A (es) Anticuerpos especificos para mmp9.
PH12014501931A1 (en) Antibodies to matrix metalloproteinase 9
MX2020011993A (es) Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide.
CN106456764A8 (zh) 用于治疗hpv阴性癌症的pdl‑1和pd‑1拮抗剂
MX2018010470A (es) Proteinas de fusion folistatina-fc recombinantes y su uso en el tratamiento de la distrofia muscular de duchenne.
EP4234013A3 (en) Methods for treating or preventing atherosclerosis by administering an inhibitor of angptl3
MX2019013523A (es) Proteínas de fusión de folistatina-fc recombinante y uso en el tratamiento de la distrofia muscular de duchenne.
MX2022004164A (es) Anticuerpos anti-flt-1 para tratar displasia broncopulmonar.
EA201891529A1 (ru) Композиции и способы обнаружения и лечения рака яичников
MX2017012828A (es) Anticuerpos anti-flt-1 para el tratamiento de distrofia muscular de duchenne.
EP4218817A3 (en) Methods for treating metabolic diseases by inhibiting myostatin activation
MX2015009819A (es) Anticuerpo humano especifico a metapneumovirus humano, o fragmento de union al antigeno del mismo.
EP3586867A3 (en) Placenta growth factor in treating duchenne muscular dystrophy
MX2017012831A (es) Anticuerpos anti receptor del factor de crecimiento endotelial vascular 1 (flt-1) en el tratamiento de displasia broncopulmonar.
SG11201810779PA (en) Method for screening antibody using patient-derived tumor spheroids

Legal Events

Date Code Title Description
FG Grant or registration